Mostrar el registro sencillo del ítem
Risk Analysis by Age on the Burden of Meningococcal Disease in Spain
dc.contributor.author | Rivero Calle, Irene | |
dc.contributor.author | Raguindin, P.F. | |
dc.contributor.author | Pardo Seco, Jacobo José | |
dc.contributor.author | Martinón Torres, Federico | |
dc.date.accessioned | 2025-08-25T12:40:19Z | |
dc.date.available | 2025-08-25T12:40:19Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Rivero-Calle I, Raguindin PF, Pardo-Seco J, Martinon-Torres F. Risk Analysis by Age on the Burden of Meningococcal Disease in Spain. Vaccines. 2022;10(4). | |
dc.identifier.issn | 2076-393X | |
dc.identifier.other | https://portalcientifico.sergas.gal/documentos/628009ae3333e458234bb83c | * |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/20495 | |
dc.description.abstract | We conducted an age-based risk analysis of meningococcal disease in Spain to provide prospects on a rational vaccine schedule in pediatrics. We used the National Hospital Registry to estimate meningococcal hospitalization rate. Population census for each year was used as the denominator in computing the hospitalization rate. We computed the odds ratio of each age using <1 year old as a reference group. From 1998 to 2017, 13,554 hospitalized cases were diagnosed, with a declining trend across the years. Infants (<1 year, n = 2425) and children (1-14 years, n = 6053) comprised the majority of all hospitalized meningococcal disease in Spain (62.5% or 8474/13,554). The incidence of hospitalization decreased dramatically with age from 56.2/100,000 in <1-year-old children to 1.3/100,000 in >5-year-old children. There was a dramatic decline in risk in 1 year (OR 0.58) to 4 years of age (OR 0.21). The risk continued to decline until 13 years old. Afterward, it had a minimal upward trajectory observed at 14-17 years old (OR 0.08). Infants and adolescents are at continued risk of invasive meningococcal disease in Spain. The highest risk occurs in infants. Surveillance data, together with evidence on long-term immunogenicity and capacity for herd effect, should be considered for a more relevant immunization schedule. | en |
dc.description.sponsorship | This study received support from the Instituto de Salud Carlos III through projects ReSVinext (Instituto de Salud Carlos III(ISCIII)/PI16/01569/Cofinanciado FEDER), and Enterogen (Instituto de Salud Carlos III(ISCIII)/PI19/01090/Cofinanciado FEDER) given to F.M.T. | en |
dc.language.iso | eng | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Risk Analysis by Age on the Burden of Meningococcal Disease in Spain | * |
dc.type | Article | en |
dc.authorsophos | Rivero-Calle, F. I. | |
dc.authorsophos | Raguindin, P. F. | |
dc.authorsophos | Pardo-Seco, J. | |
dc.authorsophos | Martinon, Torres | |
dc.identifier.doi | 10.3390/vaccines10040592 | |
dc.identifier.sophos | 628009ae3333e458234bb83c | |
dc.issue.number | 4 | |
dc.journal.title | Vaccines | * |
dc.page.initial | null | |
dc.relation.projectID | Instituto de Salud Carlos III [PI16/01569, PI19/01090]; FEDER | |
dc.relation.publisherversion | https://boris.unibe.ch/169428/1/Rivero-Calle_Vaccines_2022.pdf;https://mdpi-res.com/d_attachment/vaccines/vaccines-10-00592/article_deploy/vaccines-10-00592-v2.pdf?version=1649904322 | es |
dc.rights.accessRights | openAccess | |
dc.subject.keyword | AS Santiago | es |
dc.subject.keyword | CHUS | es |
dc.subject.keyword | IDIS | es |
dc.typefides | Artículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis) | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 10 |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
